Nonalcoholic fatty liver disease: Diagnosis, pathogenesis, and management

Turkish Journal of Gastroenterology

Volumn 25, Issue 2, 2014, Pages 127-132

  Başaranoǧlu, Metin ^a   Örmeci, Necati ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Intestinal microbiota; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CARBOHYDRATE; EXENDIN 4; EZETIMIBE; FAT; FAT DROPLET; FATTY ACID; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PENTOXIFYLLINE; SITAGLIPTIN; TETRAHYDROLIPSTATIN; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; ANTIOXIDANT;

ABDOMINAL PAIN; COMPUTER ASSISTED TOMOGRAPHY; FATTY ACID SYNTHESIS; GLUCONEOGENESIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; LIVER CELL DAMAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; INTESTINE; LIFESTYLE; LIVER CELL; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY;

ANTIOXIDANTS; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTESTINES; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS;

EID: 84905485294     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.5152/tjg.2014.7675     Document Type: Review

References (76)

1. Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 2014; 59: 2178-87. [CrossRef]
2. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2014. doi: 10.1016/j.cgh.2014.04.014. [Epub ahead of print]. [CrossRef]
3. Tilg H, Moschen AR. Evolving therapies for non-alcoholic steatohepatitis. Expert Opin Drug Discov 2014; 9: 687-96. [CrossRef]
4. Miyake T, Kumagi T, Hirooka M, et al. Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study. J Gastroenterol 2014. [Epub ahead of print]. [CrossRef]
5. Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improved survival of patients with diabetes. Hepatology 2014. doi: 10.1002/hep.27199. [Epub ahead of print]. [CrossRef]
6. Maddur H, Neuschwander-Tetri BA. More evidence that probiotics may have a role in treating fatty liver disease. Am J Clin Nutr 2014; 99: 425-6. [CrossRef]
7. Sonsuz A, Basaranoglu M, Bilir M, Senturk H, Akin P. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2002; 97: 495. [CrossRef] (Pubitemid 34160792)
8. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastro 2002; 97: 1496-500. [CrossRef] (Pubitemid 34664799)
9. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastro 2004; 99: 292-8. [CrossRef] (Pubitemid 38279872)
10. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10. [CrossRef]
11. Basaranoglu M, Sonsuz A, Senturk H, Akin P. The low incidence of primary liver disease in patients with nonalcoholic steatohepatitis. J Hepatol 2001; 35: 684-5. [CrossRef] (Pubitemid 33078284)
12. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19. [CrossRef] (Pubitemid 36538699)
13. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52. [CrossRef] (Pubitemid 39071617)
14. Crespo J, Cayón A, Fernández-Gil P, et al. Gene expression of tumor necrosis factor a and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63. [CrossRef] (Pubitemid 33096588)
15. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-9. [CrossRef] (Pubitemid 34810360)
16. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557-62. [CrossRef] (Pubitemid 27136914)
17. Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003; 36: 371. [CrossRef] (Pubitemid 36331626)
18. Sonsuz A, Basaranoglu M, Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 1370-1. [CrossRef] (Pubitemid 30263549)
19. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008; 295: G987-95. [CrossRef]
20. Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 2223-6. [CrossRef]
21. Basaranoglu M, Turhan N, Sonsuz A, Basaranoglu G. Mallory-Denk Bodies in chronic hepatitis. World J Gastroenterol 2011; 17: 2172-7. [CrossRef]
22. Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 2011; 17: 4055-62. [CrossRef]
23. Lehr S, Hartwig S, Sell H. Adipokines: A treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 2012; 6: 91-101. [CrossRef]
24. Neuschwander-Tetri BA, Ford DA, Acharya S, et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012; 47: 941-50. [CrossRef]
25. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature 2006; 444; 1022-3. [CrossRef] (Pubitemid 46018512)
26. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-4. [CrossRef]
27. Waldram A, Holmes E, Wang Y, et al. Top-down systems biology modelling of host metabotype-microbiome associations in obese rodents. J Proteome Res 2009; 8: 2361-75. [CrossRef]
28. Xu J, Mahowald MA, Ley RE, et al. Evolution of symbiotic bacteria in the distal human intestine. PLoS Biol 2007; 5: e156. [CrossRef]
29. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-9. [CrossRef] (Pubitemid 43839542)
30. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-10. [CrossRef] (Pubitemid 47598620)
31. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718-23. [CrossRef] (Pubitemid 39473554)
32. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007; 104: 979-84. [CrossRef] (Pubitemid 46154722)
33. Matarese G, La Cava A. The intricate interface between immune system and metabolism. Trends Immuno 2004; l25: 193-200.
34. Samuel BS, Shaito A, Motoike T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 2008; 105: 16767-72. [CrossRef]
35. Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 2009; 9: 737-43. [CrossRef]
36. Lajunen T, Vikatmaa P, Bloigu A, et al. Chlamydial LPS and high-sensitivity CRP levels in serum are associated with an elevated body mass index in patients with cardiovascular disease. Innate Immun 2008; 14: 375-82. [CrossRef]
37. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-92. (Pubitemid 350126229)
38. Reigstad CS, Lundén GO, Felin J, Bäckhed F. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS One 2009; 4: e5842. [CrossRef]
39. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384. [CrossRef] (Pubitemid 29349772)
40. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2013; 19: 6911-8. [CrossRef]
41. Durazzo M, Belci P, Collo A, Grisoglio E, Bo S. Focus on therapeutic trategies of nonalcoholic fatty liver disease. Int J Hepatol 2012; 2012: 464706.
42. Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab 2011; 2: 211-25. [CrossRef]
43. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012; 32: 22-9. [CrossRef]
44. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010; 32: 121-37. [CrossRef]
45. Andersen CJ, Fernandez ML. Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord 2013; 14: 241-54. [CrossRef]
46. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: Current issues and novel treatment approaches. Drugs 2013; 73: 1-14. [CrossRef]
47. Pietu F, Guillaud O, Walter T, et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clin Res Hepatol Gastroenterol 2012; 36: 146-55. [CrossRef]
48. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomized trials. Diabetologia 2012; 55: 885-904. [CrossRef]
49. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15. [CrossRef] (Pubitemid 40037642)
50. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307. [CrossRef] (Pubitemid 44837778)
51. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84. [CrossRef]
52. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10. [CrossRef] (Pubitemid 351916703)
53. Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 200-8. [CrossRef]
54. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85. [CrossRef]
55. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in type-2 diabetes mellitus independent of weight changes. J Diabetes Complications 2010; 24: 289-96. [CrossRef]
56. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet 2010; 376: 1916-22. [CrossRef]
57. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-4. [CrossRef]
58. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of NASH. Hepatology 2008; 48: 474-86. [CrossRef]
59. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: The significance of dietary cholesterol. Scand J Gastroenterol 2009; 44: 471-7. [CrossRef]
60. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-56. [CrossRef]
61. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011; 96: 350-3. [CrossRef]
62. Caldwell SH, Argo CK, Henry TD, et al. Dissociated histological and metabolic effects of omega-3 (3,000 mg/d) vs. placebo with both exercise and diet in a double-blind randomized controlled trial of NASH. J Hep 2011; 54: S8. [CrossRef]
63. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-8. [CrossRef] (Pubitemid 36399242)
64. Seo YS, Kim JH, Jo NY, et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008; 23: 102-9. (Pubitemid 350265194)
65. Buranawui W, Thung-u-thaisri P, Pramoolsinsap C, et al. Pentoxifylline for treatment of non-alcoholic fatty liver disease (NAFLD): A randomized, placebo-controlled study. Gastroenterology 2010; A330: 2161.
66. Zein CO, Yerian LM, Gogate P et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-9. [CrossRef]
67. Loguercio C, Federico A, Trappoliere M, et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease. Dig Dis Sci 2007; 52: 2387-95. [CrossRef] (Pubitemid 47246522)
68. Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: A systematic review and meta-analysis. Mol Biol Rep 2012; 39: 9715-22. [CrossRef]
69. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 (Suppl 1): S60-89. [CrossRef]
70. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl 1): S34-59. [CrossRef]
71. Bruggmann P, Berg T, Øvrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 (Suppl 1): S5-33. [CrossRef]
72. Palabiyikoǧlu M, Ormeci N, Ekiz F, et al. Amantadine in non-responder patients with chronic hepatitis C: A randomized prospective study. Hepatogastroenterology 2012; 59: 1911-4.
73. Örmeci N, Erdem H. Basic answers to complicated questions for the course of chronic hepatitis C treatment. Expert Rev Gastroenterol Hepatol 2012; 6: 371-82. [CrossRef]
74. Ormeci N, Bölükbaş F, Erden E, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology 2011; 58: 1648-53.
75. Shi KQ, Wu FL, Liu WY, et al. Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. Mol Biol Rep 2014. doi: 10.1007/s11033-014-3342-z. [Epub ahead of print]. [CrossRef]
76. Lin XF, Shi KQ, You J, Liu WY, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: A large study. Mol Biol Rep 2014; 41: 2989-97. [CrossRef]